WuXi AppTec Appoints Dr. Frederick H. Hausheer as Chief Medical Officer

SHANGHAI and AUSTIN, Texas, April 8, 2019 /PRNewswire/ -- WuXi AppTec, a leading global pharmaceutical and medical device open-access capability and technology platform company, today announces the appointment of Dr. Frederick H. Hausheer as Chief Medical Officer for the company.

In this executive role, Dr. Hausheer will provide medical, scientific and operational leadership to WuXi Clinical operations in the United States, China and other territories. In addition, he will play a key role in forging and maintaining strong connections between our customers and WuXi's business units by providing inputs on medical and clinical development strategies aimed at seamless integration from preclinical translational research and development into first-in-human studies, as well as for Phase I-IV clinical development plans for our customers.

Dr. Hausheer brings more than 30 years' experience in global oncology clinical drug development and translational science and medicine in commercial and academic settings. He has extensive experience in translational/IND programs, clinical trial design, commercial clinical development, and involvement in regulatory interactions for novel agents spanning from pre-IND and Phase I-III development in the United States, China, Europe, Japan and other territories.

"We're very excited to welcome Dr. Hausheer onboard as our Chief Medical Officer," said Mr. Edward Hu, Co-CEO of WuXi AppTec. "Dr. Hausheer's rich experience in global oncology clinical drug development and translational science and medicine makes him ideally suited to taking this role. We are confident in his leadership to strengthen WuXi's clinical development capabilities and capacity globally, and enable more customers to develop better medicine faster to benefit patients around the world."

Prior to joining WuXi, Dr. Hausheer held CEO and CMO positions with several Biopharma companies, and was the Founder and Chairman of BioNumerik Pharmaceuticals. He has also served as a business advisory board member to JP Morgan Chase, the Whittaker Institute at Johns Hopkins, and the National Cancer Institute. Early in his career he served on the National Cancer Institute (NCI) Experimental Therapeutics Section, the NCI Decision Network Panel, and the NCI Institutional Review Board, followed by extensive involvement in national and international Phase I-III clinical trials involving novel treatments for lung, breast, ovarian and other malignancies.

Dr. Hausheer obtained his MD at the University of Missouri, School of Medicine and then became a faculty member at the Johns Hopkins Oncology Center, where he focused on the development of novel experimental therapeutics and pharmacology. He currently holds adjunct professorships at the University of Missouri in Internal Medicine and Oncology and The Johns Hopkins Oncology Center in Medical Oncology. He is an inventor/co-inventor on more than 400 issued United States and international patents.

About WuXi AppTec
WuXi AppTec is a leading global pharmaceutical and medical device open-access capability and technology platform company with global operations. As an innovation-driven and customer-focused company, WuXi AppTec provides a broad and integrated portfolio of services to help our worldwide customers and partners shorten the discovery and development time and lower the cost of drug and medical device R&D through cost-effective and efficient solutions. With its industry-leading capabilities such as small molecule R&D and manufacturing, cell therapy and gene therapy R&D and manufacturing, and medical device testing, WuXi platform is enabling more than 3,500 innovative collaborators from more than 30 countries to bring innovative healthcare products to patients, and to fulfill WuXi's dream that "every drug can be made and every disease can be treated." Please visit: http://www.wuxiapptec.com

Cision View original content:http://www.prnewswire.com/news-releases/wuxi-apptec-appoints-dr-frederick-h-hausheer-as-chief-medical-officer-300825787.html

Related Links :


Look out for further updates on our Facebook fan page!

Related Articles

  • 【人才管理】社會撕裂 = 職場撕裂?HR提建議免影響工作情緒


  • 【人才管理】打工仔批公司孤寒 「度縮」行徑逐個講


  • 【人才管理】老細對罷工4種態度 網民︰政治問題老細解決?


  • 【企業管理】港職場兩性未平等 女高層流失率高


  • 【職場辛酸史】素食餐廳禁員工食肉 如有發現立即解僱


  • Tesla被爆環境惡劣 員工:如生產地獄


  • 因「道德」問題被炒? 有員工被大企秋後算帳離職


  • 返工「尋開心」須集齊3大因素

    【晴報專訊】問你一個問題:「你在工作中找到快樂嗎?」你會如何回答?原來世上六成員工都答「否」。不開心的員工會為公司帶來成功嗎?研究和分析公司總裁米高布殊(Michael C. Bush)指,要員工快樂,不只是提供金錢和福利,亦取決於公司對待他們的方式。

  • Agoda、Booking.com、KAYAK邊個最好用?幕後老闆現身解說


  • 美企進駐香港︰港專才不遜矽谷

    【經濟日報專訊】估值逾12億美元(約93億港元)的美國醫療保險公司Clover,今年初登陸堅尼地城一間共享工作間內。其主席兼首席技術總監蔡淙健(Andrew Toy)表示,香港將成為公司的技術中心,今年目標在港聘30名軟件工程師;其工程副總裁朱煒(David Zhu)亦在港坐鎮,同時負責發展國際技術夥伴關係。